Chen, Chung-Hwan
Elsalmawy, Abdulaziz H.
Ish-Shalom, Sophia
Lim, Seung-Jae
AlAli, Nadia S.
Cunha-Borges, Joao L.
Yang, Huilin
Casas, Noemi
Altan, Lale
Belaya, Zhanna
Marin, Fernando
Moll, Thomas
Gurbuz, Sirel
Brnabic, Alan
Pavo, Imre
Florez, Sandra http://orcid.org/0000-0003-2902-2564
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 9 June 2021
Accepted: 20 July 2021
First Online: 20 August 2021
Declarations
:
: S. Ish-Shalom: Grants from Eli Lilly and Company, lecture fees from Eli Lilly and Company, Medison, CTZ, Dexel, Novo Nordisk, Teva, Boehringer Ingelheim, Zamal and advisory fees from Entera Bio and Medison. N. Casas: Speaker fees from Eli Lilly and Company, Amgen and Pfizer. L. Altan: Acted on an advisory board for Eli Lilly and Company and received speaker fees from Eli Lilly and Company. F. Marin: Former employee at Eli Lilly and Company. T Moll: Former employee and shareholder at Eli Lilly and Company. S. Gurbuz, A. Brnabic, I. Pavo, and S. Florez: Employees and shareholders at Eli Lilly and Company. The authors C. H. Chen, A. Elsalmawy, S. J. Lim, N. Al Ali, J. Borges, H. Yang, and Z. Belaya declare that they have no conflict of interest.
: The ALAFOS study was conducted in accordance with the Declaration of Helsinki and was approved by the appropriate local body in each country.
: Informed consent was obtained from all individual participants included in the study.